Encochleated amphotericin B - Matinas BioPharma

Drug Profile

Encochleated amphotericin B - Matinas BioPharma

Alternative Names: CAmB; MAT 2203

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Aquarius Biotechnologies; Matinas BioPharma
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Candidiasis; Mycoses; Vulvovaginal candidiasis
  • Preclinical Aspergillosis; Cryptococcosis; Visceral leishmaniasis

Most Recent Events

  • 20 Jul 2018 Pharmacodynamics data from a preclinical trials in Candidiasis presented at the ASM Microbe 2018 (AASM-2018)
  • 06 Jun 2018 Matinas BioPharma plans a pivotal phase II trial for prevention of Mycoses (in patients with Acute myeloid leukaemia and Acute lymphoblastic leukaemia) in the first half of 2019 (NCT03187691)
  • 16 Mar 2018 Matinas BioPharma plans a phase II trial for Candidiasis in first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top